On efficacy, at least, BeOne’s BTK degrader shows an edge.
ApexOnco Front Page
Recent articles
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Key FDA decisions are expected to face delays.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
